RenovoRx to Participate at the Canaccord Genuity MedTech Diagnostics and Digital Health & Services Forum
Key Highlights
- ➤November 11 presentation to review third-quarter 2026 results and commercial execution
- ➤RenovoCath sales reached $1.1 million in 2025
- ➤Q2 2026 RenovoCath revenue hit record $909,000
- ➤TIGeR-PaC Phase III trial fully enrolled in August 2026
- ➤TIGeR-PaC topline data expected in the second half of 2027
MOUNTAIN VIEW, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath(®), a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, and Mark Voll, Chief Financial Officer, are scheduled to present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum being held on November 11, 2026 in New York, NY.
Mr. Bagai and Mr. Voll plan to review RenovoRx’s third quarter 2026 financial and business results and its continued commercial execution. They will also discuss the factors driving commercial growth and increased physician adoption of the patented Trans-Arterial Micro-Perfusion (TAMP™) platform, enabled by RenovoCath, as physicians expand its use across additional solid tumor types.
Get started
Create a free account to read the full story.